clinical trial · NCT03580655
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Advanced Systemic MastocytosisAggressive Systemic MastocytosisSystemic Mastocytosis With an Associated Hematologic NeoplasmMast Cell LeukemiaAvapritinib
brief summary
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)
started
Nov 21, 2018
primary completion
Dec 18, 2024
completion
Dec 18, 2024
last updated
Apr 24, 2026
official title
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol